Literature DB >> 26927805

The Role of Aldosterone in Obesity-Related Hypertension.

Wakako Kawarazaki1, Toshiro Fujita2.   

Abstract

Obese subjects often have hypertension and related cardiovascular and renal diseases, and this has become a serious worldwide health problem. In obese subjects, impaired renal-pressure natriuresis causes sodium retention, leading to the development of salt-sensitive hypertension. Physical compression of the kidneys by visceral fat and activation of the sympathetic nervous system, renin-angiotensin systems (RAS), and aldosterone/mineralocorticoid receptor (MR) system are involved in this mechanism. Obese subjects often exhibit hyperaldosteronism, with increased salt sensitivity of blood pressure (BP). Adipose tissue excretes aldosterone-releasing factors, thereby stimulating aldosterone secretion independently of the systemic RAS, and aldosterone/MR activation plays a key role in the development of hypertension and organ damage in obesity. In obese subjects, both salt sensitivity of BP, enhanced by obesity-related metabolic disorders including aldosterone excess, and increased dietary sodium intake are closely related to the incidence of hypertension. Some salt sensitivity-related gene variants affect the risk of obesity, and together with salt intake, its combination is possibly associated with the development of hypertension in obese subjects. With high salt levels common in modern diets, salt restriction and weight control are undoubtedly important. However, not only MR blockade but also new diagnostic modalities and therapies targeting and modifying genes that are related to salt sensitivity, obesity, or RAS regulation are expected to prevent obesity and obesity-related hypertension. © American Journal of Hypertension, Ltd 2016. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  aldosterone; blood pressure; hypertension; obesity; salt; salt sensitivity of blood pressure.

Mesh:

Substances:

Year:  2016        PMID: 26927805      PMCID: PMC4886496          DOI: 10.1093/ajh/hpw003

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  107 in total

1.  50th anniversary of aldosterone.

Authors:  Jonathan S Williams; Gordon H Williams
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

2.  Left ventricular systolic function in primary aldosteronism and hypertension.

Authors:  G P Rossi; A Sacchetto; E Pavan; R Scognamiglio; M Pietra; A C Pessina
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

3.  Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual.

Authors:  Marie-Pierre St-Onge; Ian Janssen; Steven B Heymsfield
Journal:  Diabetes Care       Date:  2004-09       Impact factor: 19.112

4.  A novel adipokine CTRP1 stimulates aldosterone production.

Authors:  Jun Ho Jeon; Kun-yong Kim; Jae Hyeong Kim; Ahmi Baek; Hyungin Cho; Young Ho Lee; Jong Wan Kim; Dohee Kim; Seung Hyun Han; Jong-Seok Lim; Keun Il Kim; Do Young Yoon; Soo-Hyun Kim; Goo Taeg Oh; Eunjoon Kim; Young Yang
Journal:  FASEB J       Date:  2008-01-02       Impact factor: 5.191

5.  Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion.

Authors:  Theodore L Goodfriend; Dennis L Ball; Brent M Egan; William B Campbell; Kasem Nithipatikom
Journal:  Hypertension       Date:  2004-01-12       Impact factor: 10.190

6.  High salt intake: independent risk factor for obesity?

Authors:  Yuan Ma; Feng J He; Graham A MacGregor
Journal:  Hypertension       Date:  2015-08-03       Impact factor: 10.190

7.  Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.

Authors:  Murray Epstein; Gordon H Williams; Myron Weinberger; Andrew Lewin; Scott Krause; Robin Mukherjee; Rajiv Patni; Bruce Beckerman
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-19       Impact factor: 8.237

8.  Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.

Authors:  H B Hubert; M Feinleib; P M McNamara; W P Castelli
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

9.  The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients.

Authors:  Anna Maria Di Blasio; Elisabeth F C van Rossum; Sabrina Maestrini; Maria Elisa Berselli; Mariantonella Tagliaferri; Francesca Podestà; Jan W Koper; Antonio Liuzzi; Steven W J Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  2003-07       Impact factor: 3.478

Review 10.  Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis.

Authors:  Katherine M Flegal; Brian K Kit; Heather Orpana; Barry I Graubard
Journal:  JAMA       Date:  2013-01-02       Impact factor: 56.272

View more
  44 in total

Review 1.  Very low-density lipoprotein (VLDL)-induced signals mediating aldosterone production.

Authors:  Ying-Ying Tsai; William E Rainey; Wendy B Bollag
Journal:  J Endocrinol       Date:  2016-12-02       Impact factor: 4.286

Review 2.  Kidney and epigenetic mechanisms of salt-sensitive hypertension.

Authors:  Wakako Kawarazaki; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2021-02-24       Impact factor: 28.314

Review 3.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

Review 4.  Obesity, hypertension and aldosterone: is leptin the link?

Authors:  Ding Xie; Wendy B Bollag
Journal:  J Endocrinol       Date:  2016-06-01       Impact factor: 4.286

5.  VLDL-activated cell signaling pathways that stimulate adrenal cell aldosterone production.

Authors:  Ying-Ying Tsai; William E Rainey; Maribeth H Johnson; Wendy B Bollag
Journal:  Mol Cell Endocrinol       Date:  2016-05-21       Impact factor: 4.102

Review 6.  The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature.

Authors:  Zachary Belden; Jeffrey A Deiuliis; Mirela Dobre; Sanjay Rajagopalan
Journal:  Am J Nephrol       Date:  2017-10-10       Impact factor: 3.754

7.  Hypertension, C Reactive Protein and Metabolic Profile: What is the Scenario in Patients Undergoing Arteriography?

Authors:  Ricardo Jose Tofano; Sandra Maria Barbalho; Marcelo Dib Bechara; Karina Quesada; Claudemir Gregorio Mendes; Marie Oshiiwa
Journal:  J Clin Diagn Res       Date:  2017-08-01

Review 8.  Anti-Inflammatory Effects of Melatonin in Obesity and Hypertension.

Authors:  Natalia Jorgelina Prado; León Ferder; Walter Manucha; Emiliano Raúl Diez
Journal:  Curr Hypertens Rep       Date:  2018-05-09       Impact factor: 5.369

9.  Nutritional Genomics of Cardiovascular Disease.

Authors:  V Saroja Voruganti
Journal:  Curr Genet Med Rep       Date:  2018-04-30

Review 10.  Pathophysiology and treatment of obesity-related hypertension.

Authors:  Steven G Chrysant
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-03-24       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.